SRP-9004

DRUG2 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Limb Girdle Muscular DystrophyLimb Girdle Muscular Dystrophy Type 2D/R3Limb-Girdle Muscular Dystrophy, Type 2D

Phase 1

A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)

CompletedNCT01976091

Sarepta Therapeutics, Inc.Limb-Girdle Muscular Dystrophy, Type 2D

Start: 2015-02-01End: 2019-03-14Updated: 2023-06-15

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

TerminatedNCT06747273

Sarepta Therapeutics, Inc.Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type 2D/R3

Start: 2025-01-09End: 2025-06-18Updated: 2025-09-04